Biomarker-driven therapeutic management of alzheimer's disease: Establishing the foundations

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 1, 2014, Pages 67-77

  Cummings, J ^a   Zhong, K ^a  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN METABOLISM; BRAIN SIZE; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; CORTICOBASAL DEGENERATION; CREUTZFELDT JAKOB DISEASE; DISEASE COURSE; FRONTOTEMPORAL DEMENTIA; HUMAN; HYDROCORTISONE BLOOD LEVEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN BLOOD LEVEL; TRAUMATIC BRAIN INJURY;

EID: 84890948464     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.205     Document Type: Article

References (92)

1. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 8, 131-168 (2012).
2. Thies, W. & Bleiler, L.; Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 9, 208-245 (2013).
3. Cummings, J.L. Use of cholinesterase inhibitors in clinical practice: evidencebased recommendations. Am. J. Geriatr. Psychiatry 11, 131-145 (2003). (Pubitemid 36254187)
4. Massoud, F. & Léger, G.C. Pharmacological treatment of Alzheimer disease. Can. J. Psychiatry. 56, 579-588 (2011).
5. Cummings, J. et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm-) in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 33, 341-353 (2012).
6. Farlow, M. et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurol. 11, 57 (2011).
7. Huang, Y. & Mucke, L. Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222 (2012).
8. Katsuno, M., Tanaka, F. & Sobue, G. Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatr. 83, 329-335 (2012).
9. Salloway, S., Mintzer, J., Weiner, M.F. & Cummings, J.L. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement. 4, 65-79 (2008).
10. Brunden, K.R., Trojanowski, J.Q. & Lee, V.M. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat. Rev. Drug Discov. 8, 783-793 (2009).
11. Tuszynski, M.H. et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11, 551-555 (2005). (Pubitemid 40691288)
12. Cummings, J. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease? Biol. Psychiatry 68, 876-878 (2010).
13. Becker, R.E. & Greig, N.H. Increasing the success rate for Alzheimer's disease drug discovery and development. Expert Opin. Drug Discov. 7, 367-370 (2012).
14. Fillit, H.M. et al. Barriers to drug discovery and development for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 16 (suppl. 1), S1-S8 (2002). (Pubitemid 34625821)
15. Cummings, J.L. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement. 7, e13-e44 (2011).
16. Cummings, J.L. et al. Alzheimer's disease drug development: translational neuroscience strategies. CNS Spectr. 11, 1-11 (2013).
17. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
18. Coley, N., Andrieu, S., Delrieu, J., Voisin, T. & Vellas, B. Biomarkers in Alzheimer's disease: not yet surrogate endpoints. Ann. N. Y. Acad. Sci. 1180, 119-124 (2009).
19. Danhof, M., Alvan, G., Dahl, S.G., Kuhlmann, J. & Paintaud, G. Mechanismbased pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm. Res. 22, 1432-1437 (2005). (Pubitemid 41215882)
20. Dickerson, B.C. & Sperling, R.A. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx 2, 348-360 (2005). (Pubitemid 40471441)
21. Guerreiro, R. et al.; Alzheimer Genetic Analysis Group. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117-127 (2013).
22. Guo, L.H. et al. SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 262, 529-534 (2012).
23. Morgan, K. The three new pathways leading to Alzheimer's disease. Neuropathol. Appl. Neurobiol. 37, 353-357 (2011).
24. Roses, A.D. An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. Arch. Neurol. 67, 536-541 (2010).
25. Tanzi, R.E. The genetics of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, 1-10 (2012).
26. Reiman, E.M. et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J. Alzheimers Dis. 26 (suppl. 3), 321-329 (2011).
27. Bateman, R.J. et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res. Ther. 3, 1 (2011).
28. Hampel, H. et al.; Oxford Task Force Group. Biomarkers for Alzheimer's disease therapeutic trials. Prog. Neurobiol. 95, 579-593 (2011).
29. Wu, L., Rosa-Neto, P. & Gauthier, S. Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. Mol. Diagn. Ther. 15, 313-325 (2011).
30. Albert, M.S. et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270-279 (2011).
31. Dubois, B. et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734-746 (2007). (Pubitemid 47058377)
32. Dubois, B. et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9, 1118-1127 (2010).
33. Bateman, R.J. et al.; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804 (2012).
34. Villemagne, V.L. et al.; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12, 357-367 (2013).
35. Sabbagh, J.J., Kinney, J.W. & Cummings, J.L. Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. Neurobiol. Aging 34, 169-183 (2013).
36. Bales, K.R. The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update. Expert Opin. Drug Discov. 7, 281-297 (2012).
37. Prinz, F., Schlange, T. & Asadullah, K. Believe it or not: how much can we rely on published data on potential drug targets? Nat. Rev. Drug Discov. 10, 712 (2011).
38. Jack, C.R. Jr et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 257-262 (2011).
39. McKhann, G.M. et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 263-269 (2011).
40. Sperling, R. et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 11, 241-249 (2012).
41. Pillai, J.A. & Cummings, J.L. Clinical trials in predementia stages of Alzheimer disease. Med. Clin. North Am. 97, 439-457 (2013).
42. Bateman, R.J., Munsell, L.Y., Morris, J.C., Swarm, R., Yarasheski, K.E. & Holtzman, D.M. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12, 856-861 (2006). (Pubitemid 44050079)
43. Wildsmith, K.R. et al. In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS ONE 7, e38013 (2012).
44. Bateman, R.J. et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann. Neurol. 66, 48-54 (2009).
45. Fleisher, A.S. et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65, 1031-1038 (2008).
46. Portelius, E. et al. Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease. J. Alzheimers Dis. 31, 335-341 (2012).
47. Sankaranarayanan, S. et al. First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J. Pharmacol. Exp. Ther. 328, 131-140 (2009).
48. Tai, L.M. et al. The dynamics of Aβ distribution after γ-secretase inhibitor treatment, as determined by experimental and modelling approaches in a wild type rat. J. Pharmacokinet. Pharmacodyn. 39, 227-237 (2012).
49. Wu, G. et al. Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease. J. Neurosci. Res. 90, 2247-2258 (2012).
50. Verheijen, J.H. et al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin. Chem. 52, 1168-1174 (2006). (Pubitemid 43794431)
51. Cummings, J.L. Defining and labeling disease-modifying treatments for Alzheimer's disease. Alzheimers Dement. 5, 406-418 (2009).
52. Beach, T.G., Monsell, S.E., Phillips, L.E. & Kukull, W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J. Neuropathol. Exp. Neurol. 71, 266-273 (2012).
53. Cummings, J.L. Alzheimer's disease clinical trials: changing the paradigm. Curr. Psychiatry Rep. 13, 437-442 (2011).
54. Leung, K.K., Bartlett, J.W., Barnes, J., Manning, E.N., Ourselin, S. & Fox, N.C.; Alzheimer's Disease Neuroimaging Initiative. Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. Neurology 80, 648-654 (2013).
55. Fleisher, A.S. et al.; Alzheimer's Disease Cooperative Study. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 77, 1263-1271 (2011).
56. Schott, J.M., Bartlett, J.W., Barnes, J., Leung, K.K., Ourselin, S. & Fox, N.C.; Alzheimer's Disease Neuroimaging Initiative investigators. Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. Neurobiol. Aging 31, 1452-62, 1462.e1 (2010).
57. Holland, D., McEvoy, L.K., Desikan, R.S. & Dale, A.M.; Alzheimer's Disease Neuroimaging Initiative. Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS ONE 7, e47739 (2012).
58. Fox, N.C. et al.; AN1792(QS-21)-201 Study. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64, 1563-1572 (2005). (Pubitemid 40617692)
59. Fagan, A.M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59, 512-519 (2006). (Pubitemid 43358072)
60. Jack, C.R. Jr et al. Brain β-amyloid load approaches a plateau. Neurology 80, 890-896 (2013).
61. Rinne, J.O. et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9, 363-372 (2010).
62. Blennow, K., Zetterberg, H. & Fagan, A.M. Fluid biomarkers in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006221 (2012).
63. van Rossum, I.A. et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology 79, 1809-1816 (2012).
64. Desikan, R.S. et al.; Alzheimer's Disease Neuroimaging Initiative. Amyloid- β-associated clinical decline occurs only in the presence of elevated P-tau. Arch. Neurol. 69, 709-713 (2012).
65. Mattsson, N. et al.; Alzheimer's Association QC Program Work Group. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 9, 251-261 (2013).
66. Fodero-Tavoletti, M.T. et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 134, 1089-1100 (2011).
67. Zhang, W. et al. A highly selective and specific PET tracer for imaging of tau pathologies. J. Alzheimers Dis. 31, 601-612 (2012).
68. Herholz, K. Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease. Biomark. Med. 6, 431-439 (2012).
69. Reiman, E.M.; Alzheimer's Disease Biomarkers Working Group for the Alliance for Aging Research. Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments. Neurobiol. Aging 32 (suppl. 1), S44-S47 (2011).
70. Boecke, J.D. et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch. Neurol. 69, 1318-1325 (2012).
71. Thambisetty, M. & Lovestone, S. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark. Med. 4, 65-79 (2010).
72. Tiseo, P.J., Rogers, S.L. & Friedhoff, L.T. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br. J. Clin. Pharmacol. 46 (suppl. 1), 13-18 (1998). (Pubitemid 29197009)
73. Bohnen, N.I. et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatr. 76, 315-319 (2005). (Pubitemid 40299116)
74. Kaasinen, V. et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J. Clin. Psychopharmacol. 22, 615-620 (2002). (Pubitemid 35416788)
75. Farlow, M.R. et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin. Ther. 32, 1234- 1251 (2010).
76. Cummings, J.L., Geldmacher, D., Farlow, M., Sabbagh, M., Christensen, D. & Betz, P. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. CNS Neurosci. Ther. 19, 294-301 (2013).
77. Sperling, R.A. et al. Amyloid-related imaging abnormalities in amyloidmodifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 7, 367-385 (2011).
78. Sperling, R.A. et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280-292 (2011).
79. Salloway, S. et al.; Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070 (2009).
80. Zhang, D., Wang, Y., Zhou, L., Yuan, H. & Shen, D.; Alzheimer's Disease Neuroimaging Initiative. Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage 55, 856-867 (2011).
81. Kohannim, O. et al.; Alzheimer's Disease Neuroimaging Initiative. Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol. Aging 31, 1429-1442 (2010).
82. Goodsaid, F. & Frueh, F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J. 9, E105-E108 (2007).
83. US Food and Drug Administration. Guidance for industry (draft guidance). Enrichment strategies for clinical trials to support approval of human drugs and biological products. Rockville, MD (2012).
84. Hendrix, S.B. Requiring an amyloid-β1-42 biomarker may improve the efficiency of a study, and simulations may help in planning studies. Alzheimers Res. Ther. 3, 10 (2011).
85. Schneider, L.S., Kennedy, R.E. & Cutter, G.R.; Alzheimer's Disease Neuroimaging Initiative. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement. 6, 367-377 (2010).
86. Gold, G. et al. Clinical validity of A beta-protein deposition staging in brain aging and Alzheimer disease. J. Neuropathol. Exp. Neurol. 60, 946-952 (2001). (Pubitemid 32924120)
87. Murray, M.E., Graff-Radford, N.R., Ross, O.A., Petersen, R.C., Duara, R. & Dickson, D.W. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 10, 785-796 (2011).
88. Hoozemans, J.J., Rozemuller, A.J., van Haastert, E.S., Eikelenboom, P. & van Gool, W.A. Neuroinflammation in Alzheimer's disease wanes with age. J. Neuroinflammation 8, 171 (2011).
89. Bernick, C., Cummings, J., Raman, R., Sun, X. & Aisen, P. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch. Neurol. 69, 901-905 (2012).
90. Seppälä, T.T. et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 78, 1568-1575 (2012).
91. Zarow, C. et al. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. Ann. Neurol. 57, 896-903 (2005). (Pubitemid 40798628)
92. Lam, B., Masellis, M., Freedman, M., Stuss, D.T. & Black, S.E. Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome. Alzheimers Res. Ther. 5, 1 (2013).